This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameMafosfamide
Accession NumberDB12083
TypeSmall Molecule
GroupsInvestigational
Description

Mafosfamide has been used in trials studying the treatment of Lymphoma, Leukemia, Meningeal Neoplasm, and Brain and Central Nervous System Tumors.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII5970HH9923
CAS number88859-04-5
WeightAverage: 401.25
Monoisotopic: 399.9850065
Chemical FormulaC9H19Cl2N2O5PS2
InChI KeyPBUUPFTVAPUWDE-UGZDLDLSSA-N
InChI
InChI=1S/C9H19Cl2N2O5PS2/c10-2-4-13(5-3-11)19(14)12-9(1-6-18-19)20-7-8-21(15,16)17/h9H,1-8H2,(H,12,14)(H,15,16,17)/t9-,19-/m0/s1
IUPAC Name
2-{[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl}ethane-1-sulfonic acid
SMILES
OS(=O)(=O)CCS[[email protected]]1CCO[[email protected]@](=O)(N1)N(CCCl)CCCl
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mafosfamide.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Mafosfamide.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mafosfamide.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mafosfamide.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mafosfamide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mafosfamide.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Mafosfamide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mafosfamide.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Mafosfamide.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Mafosfamide.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mafosfamide.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mafosfamide.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Meningeal Neoplasms1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility5.54 mg/mLALOGPS
logP-0.61ALOGPS
logP-0.83ChemAxon
logS-1.9ALOGPS
pKa (Strongest Acidic)-0.9ChemAxon
pKa (Strongest Basic)0.057ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity84.86 m3·mol-1ChemAxon
Polarizability36.04 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as nitrogen mustard compounds. These are compounds having two beta-haloalkyl groups bound to a nitrogen atom.
KingdomOrganic compounds
Super ClassOrganic nitrogen compounds
ClassOrganonitrogen compounds
Sub ClassNitrogen mustard compounds
Direct ParentNitrogen mustard compounds
Alternative ParentsPhosphoric monoester diamides / Oxazaphosphinanes / Sulfonyls / Organosulfonic acids / Alkanesulfonic acids / Sulfenyl compounds / Oxacyclic compounds / Dialkylthioethers / Azacyclic compounds / Organopnictogen compounds
SubstituentsNitrogen mustard / Phosphoric monoester diamide / Organic phosphoric acid derivative / Oxazaphosphinane / Organic phosphoric acid amide / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Organosulfonic acid / Sulfonyl / Alkanesulfonic acid
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Drug created on October 20, 2016 15:19 / Updated on September 01, 2017 12:16